Merck Finalizes Purchase of Verona Pharma
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Merck's Acquisition of Verona Pharma: Merck has completed the acquisition of Verona Pharma, making it a wholly-owned subsidiary, which enhances Merck's cardio-pulmonary portfolio with the addition of Ohtuvayre (ensifentrine), a first-in-class treatment for chronic obstructive pulmonary disease (COPD).
Ohtuvayre's Significance and Approval: Ohtuvayre is the first novel inhaled therapy for COPD maintenance in over 20 years, combining bronchodilator and anti-inflammatory effects, and was approved by the FDA in June 2024.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
